Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Faxomax M
- Development stage
- Unknown
- Lead developer
- Renomed Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Faxomax M is an oral fixed-dose combination medication containing fexofenadine hydrochloride and montelukast sodium, marketed by Renomed Lifesciences. Fexofenadine is a second-generation, non-sedating H1-receptor antagonist that provides relief from allergic symptoms such as sneezing, rhinorrhea, and itchy eyes by selectively inhibiting peripheral histamine receptors. Montelukast is a selective cysteinyl leukotriene receptor antagonist that blocks the CysLT1 receptor, thereby reducing airway inflammation and bronchoconstriction. This combination is indicated for the symptomatic treatment of allergic rhinitis and the management of comorbid asthma in both adults and children. It is available in both tablet and suspension formulations as part of Renomed's wellness care product line.
- Brand names
- Faxomax MFaxomax M TabletsFaxomax M Suspension
- Other names
- Fexofenadine + Montelukast
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Faxomax M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Faxomax M.